With Factor VIIa Tie-up, Wyeth And Catalyst Look To Take On Novo Nordisk
This article was originally published in The Pink Sheet Daily
Executive Summary
In their second collaboration, the pharma and the biotech aim to develop a longer-acting, more potent hemophilia drug.
You may also be interested in...
Tie-Up With MedImmune Marks Catalyst's Second Partnership Deal In A Week
The collaboration involves discovery work on undisclosed targets in the autoimmune and inflammatory disease areas.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.